What’s Driving Growth in the Vyvgart Market? Insights into Key Trends and Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
How has the vyvgart market grown in recent years?
In the past few years, the vyvgart market has seen a size increase of XX (HCAGR). The anticipated growth is from $XX million in 2024 to $XX million in 2025, with a compound annual growth rate (CAGR) of XX%. The expansion during the historic period is accredited to factors such as a surge in myasthenia gravis cases, heightened awareness of autoimmune diseases, advancements in diagnostic methods, improved healthcare facilities, and increased efforts towards patient advocacy.
How is the vyvgart market size expected to evolve during the forecast period?
Expectations for the vyvgart market size suggest a XX (FCAGR) increase in the coming years. The market is projected to reach a value of $XX million in 2029, with a compound annual growth rate (CAGR) of XX%. Numerous factors contribute to this anticipated growth, including increased demand for specialized immunotherapy, a rise in healthcare spending, broader access for patients to advanced treatments, supportive regulatory policies, and a growing number of autoimmune disorders. Emergent trends expected to drive the market throughout the projection period include an upsurge in autoimmune research investments, a preference shift towards biologics over conventional treatments, breakthroughs in recombinant antibody technology, an expanding range of therapeutic applications for IgG1 fragments, and the creation of subcutaneous formulations.
Get your vyvgart market report here!
https://www.thebusinessresearchcompany.com/report/vyvgart-global-market-report
Which key drivers are propelling the vyvgart market’s growth?
The escalating incidences of autoimmune diseases are set to fuel the expansion of the vyvgat market. Autoimmune ailments are scenarios where a person’s immune system erroneously targets and damages its own healthy cells and tissues, mistaking them as foreign or harmful entities. This augmentation in autoimmune diseases mainly stems from a blend of genetic susceptibility, environmental influences, infections, and alterations in lifestyle such as dietary habits and heightened exposure to harmful chemicals. Vyvgart (efgartigimod alfa-fcab), is employed to treat autoimmune disorders, particularly generalized myasthenia gravis (gMG), by targeting and restraining the neonatal Fc receptor (FcRn) from lowering pathogenic antibodies which contribute to the illness. For example, in August 2024, as per the Myasthenia Gravis Foundation of America, a US-based organization, myasthenia gravis impacts about 150 to 200 individuals per million globally. In the United States, it’s estimated that this malady affects 37 out of every 100,000 people. Consequently, the rising prominence of autoimmune diseases is escalating the vyvgat market growth.
What are the market segments in the vyvgart industry?
The vyvgart market covered in this report is segmented –
1) By Indication: Generalized Myasthenia Gravis (gMG); Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
2) By End User: Adult; Geriatric
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20394&type=smp
Which leading companies are shaping the growth of the vyvgart market?
Major companies operating in the vyvgart market are Argenx SE
What key trends are currently impacting the vyvgart market’s development?
In the Vyvgart market, the central trend revolves around obtaining regulatory authorizations to gain a competitive advantage. These approvals are vital for verifying the safety and efficacy of Vyvgart in the treatment of autoimmune diseases, increasing the drug’s market reach and instilling confidence in physicians and patients. As an illustration, in March 2024, the Netherlands-based immunology firm, argenx, reported that its revolutionary treatment, VYVGART (efgartigimod alfa), had been given the green light in Japan for adults afflicted with primary immune thrombocytopenia (ITP). Presented by Japan’s Ministry of Health, Labour and Welfare, this denotes the first global approval for VYVGART precisely for ITP, broadening its therapeutic uses beyond generalized myasthenia gravis (gMG). VYVGART had already received approval in various regions for gMG, including the United States and Europe. VYVGART acts as a human IgG1 antibody fragment targeting the neonatal Fc receptor (FcRn), leading to a decrease in circulating IgG autoantibodies. This new mechanism presents a fresh treatment solution for patients who have been on hold for effective therapies for this autoimmune disorder.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20394
Which geographic areas are influencing the growth of the vyvgart market?
North America was the largest region in the vyvgart market in 2024. The regions covered in the vyvgart market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Anatomic Pathology Equipment And Consumables Global Market Report 2025
Monoclonal Antibodies MAS Global Market Report 2025
https://thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report
Digital Pathology Global Market Report 2025
https://thebusinessresearchcompany.com/report/digital-pathology-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
